VIFOR-PHARMA
26.11.2021 07:02:06 CET | Business Wire | Press release
Already for the seventh consecutive year of Iron Deficiency Day, Vifor Pharma is supporting a growing international alliance including the Heart Failure Policy Network, European Kidney Health Alliance, Global Heart Hub and Croí the West of Ireland Cardiac Foundation with the aim to educate people about the importance of iron for the body and what can happen if iron levels are not properly managed. Iron Deficiency Day 2021 encourages people at risk to listen to their body, to take iron seriously and to take control over their health by seeking early diagnosis and medical help from their physician.
Iron Deficiency affects about half of the patients with chronic kidney disease2 and chronic heart failure and is associated with reduced quality of life3 , an increased risk of hospitalization4 and cardiovascular death5 . Despite the serious consequences and high prevalence, of iron deficiency, the condition remains under-recognized6 . Diagnosis and treatment of iron deficiency has been further impaired during the COVID-19 pandemic as patients have been facing limited access to healthcare, resulting in even more cases going undiagnosed.
“We are pleased to join our partners in supporting Iron Deficiency Day 2021, at a time when pressures on healthcare systems exacerbated by the pandemic mean that awareness around the importance of iron is more pertinent than ever,” commented Abbas Hussain, CEO of Vifor Pharma Group. “Together, we are dedicated to support people at risk of and living with iron deficiency or iron deficiency anemia so they can lead better, healthier lives.”
“COVID-19 is having a significant impact on access to care. With many healthcare systems facing significant backlogs, patients experiencing iron deficiency symptoms have been less likely to seek support from healthcare professionals.” said Dr. Ewa Anita Jankowska, Professor at Wroclaw Medical University, Poland. “However, iron deficiency is easily diagnosed and treatable. It is therefore vital that we raise awareness of this debilitating disease and ensure individuals understand how to recognize the symptoms and gain access to early diagnosis and treatment options.”
To learn more about the importance of early diagnosis and recognizing symptoms of iron deficiency, visit www.takeironseriously.com/raise-awareness . Use hashtags #TakeIronSeriously #IronDeficiency #IronDeficiencyDay and #IDDay2021 on Twitter and LinkedIn.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
Notes to Editors
Takeironseriously.com is intended to provide educational information to an international audience outside the US; it is available in 12 languages. All information on the site is intended for educational purposes only and should not be used to replace a discussion with a healthcare professional. All decisions regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient.
About iron deficiency
Iron plays a vital role in many bodily processes, including the production of red blood cells, effective heart and brain function, and the prevention of infection and illness. Without enough iron, the body is unable to function properly. Common symptoms include fatigue, dizziness, and shortness of breath. Iron deficiency and iron deficiency anemia is estimated to affect one in three people worldwide7 , yet despite the serious consequences and high prevalence8 , it remains an under-recognized condition.
Although iron deficiency can affect anyone, it is most prevalent in premenopausal women, pregnant woman and children under five9 . Left untreated, it can develop into iron deficiency anemia. The effects of iron deficiency differ from person to person but can be linked to an overall decline in general health and well-being10 . Even without anemia, iron deficiency can be debilitating, exacerbate an underlying chronic disease and lead to increased morbidity and mortality11 . Common symptoms include fatigue10, 12, 13 pale skin12 , brittle nails12, 14 , craving non-food items such as dirt, clay and ice15 , and an inability to concentrate10, 16 . In children, iron deficiency can significantly impair cognitive and motor development17 .
References
1. Hassan, Tamer Hasan et al. “Impact of Iron Deficiency Anemia on the Function of the Immune System in Children.” Ed. Esaki M. Shankar. Medicine 95.47 (2016): e5395. PMC. Web. 12 June 2018.
2. Wong MMY et al. Clin Kid J 2019:1–12; Rocha BML, et al. J Am Coll Cardiol. 2018;71(7):782–793.
3.
Guedes M NDT 2021. doi: 10.1093/ndt/gfab050; Enjuanes C, et al. Int J Cardiol. 2014;174(2):268–275.
4. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030, Martens P, et al. Acta Cardiol. 2018;73(2):115–123.
5. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030; Klip IT, et al. Am Heart J. 2013;165:575–82.e3.
6. Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
7. Peyrin-Biroulet L, et al. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-94.
8. World Health Organization. Worldwide prevalence of anaemia 1993-2005. 2008. Available at URL: http://apps.who.int/iris/bitstream/handle/10665/43894/9789241596657_eng.pdf;jsessionid=9C613E2F4D481EDEB9DE07986AFC
E0C7?sequence=1. Last accessed: June 2018.
9. Hercberg S, et al. Iron deficiency in Europe. Public Health Nutr
. 2007;4(2b).
10. Fernando B, et al. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4638-4643.
11. Cappellini MD et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol
. 2017 Oct;92(10):1068-1078.
12. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38.
13. Favrat, B., et al. (2014). Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One
9(4): e94217. eCollection 2014.
14. Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol
. 2010;28(4):420-5.
15. Barton JC, et al. Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Blood Disord. 2010;10:9. doi:10.1186/1471-2326-10-9.
16. Patterson A et al. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women’s Health. Qual Life Res
. 2000;9:491-497.
17. World Health Organization. Nutritional anaemias: tools for effective prevention and control. 2017. Available at URL: http://www.who.int/nutrition/publications/micronutrients/anaemias-tools-prevention-control/en/
. Last accessed: June 2018.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125006152/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors17.4.2026 09:04:00 CEST | Press release
The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme. Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing. Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible. “BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS
Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi17.4.2026 09:00:00 CEST | Press release
News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran’s SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran’s focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network’ and ‘Artificial intelligence (AI), machine learning and other software.’ Organized by FTTH Council Europe, the annual awards honor technologies that advance fiber deployment while improving scalability, operational efficiency and user experience. Voted by FTTH Conference 2026 speakers, the results reflect peer recognition for Mosai
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release
- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate
Andersen Global lancerer Andersen in Pakistan16.4.2026 22:57:00 CEST | Pressemeddelelse
Andersen Global fortsætter sin regionale vækst i Sydasien med tilføjelsen af Andersen in Pakistan som det seneste medlemsfirma, der slutter sig til den globale organisation. Efter overgangen til Andersen-brandet tilbyder virksomheden – tidligere kendt som Saafin Global Consulting – en bredt funderet praksis, der betjener kunder på tværs af brancher, herunder fremstillingsindustri, energi, finansielle tjenester, telekommunikation, sundhedsvæsen, fast ejendom og private equity. Med hovedkvarter i Islamabad leverer Andersen in Pakistan integreret support inden for skat, virksomhedsrådgivning og HR-tjenester til nationale og internationale organisationer. "Vores service er forankret i etik, styret af gennemsigtighed og bevist gennem et vedholdende engagement i præcision," udtalte Rashid Ibrahim, ledende partner hos Andersen in Pakistan. "At tage Andersen-brandet til os er en vigtig milepæl for vores firma. Det afspejler vores forpligtelse til at levere praktiske løsninger af høj kvalitet,
BTG Pactual Timberland Investment Group Completes First Close of US$ 370 Million to Newest Core Latin American Timberland Strategy16.4.2026 22:04:00 CEST | Press release
BTG Pactual Timberland Investment Group (BTG Pactual TIG), one of the world’s largest timberland investment managers, announced today that it has completed the first close of US$ 370 million in commitments to its newest core Latin America strategy. Targeting investment of US$ 1.5 billion over 5 years, the strategy focuses on large-scale, sustainably managed, core timberland assets across Chile, Uruguay and Brazil, and seeks diversification across geography, climatic zones, species, and end-markets. BTG Pactual TIG has operated in Latin America for over two decades, and has built and managed a series of scaled timberland platforms through this strategy, including the creation of three platform companies, Lumin, Vista Hermosa, and Plateau, forming part of the firm’s global US$ 7.5 billion portfolio. The formation of Plateau, announced in August 2025, marked the first acquisition under this new strategy. Created in partnership with Klabin S.A. (Klabin) and British Columbia Investment Mana
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
